Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

4502

株式のランク #377
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
株価
$40.31
時価総額
$64.13B
変化(1日)
0.82%
変化(1年)
42.59%
国
JP
取引 Takeda Pharmaceutical Company Limited (4502)

カテゴリー

Healthcare
Takeda Pharmaceutical Company Limited(4502)の収益
Oct 2026 時点の収益 TTM: 0
Takeda Pharmaceutical Company Limited の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Takeda Pharmaceutical Company Limited の収益履歴(2026 ~ 2026)
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。